IQVIA Holdings Inc.

IQVIA Holdings Inc. is the largest global provider of clinical research services, healthcare data, and commercial analytics to the life sciences industry, generating $16.3 billion in revenue in fiscal 2025 from more than 10,000 clients across over 100 countries. The company was formed in 2016 through the merger of Quintiles, the dominant clinical research organization, and IMS Health, the dominant pharmaceutical data provider — a combination that created an entity with no true peer in either scale or scope. IQVIA now sits at the intersection of drug development and healthcare information, with approximately 93,000 employees, $34.2 billion in contracted clinical backlog, and a proprietary data estate spanning 68 petabytes and more than 1.2 billion non-identified patient records.

The file turns on a central tension that has only intensified with the arrival of agentic AI: IQVIA's business is built on the premise that its proprietary data, domain expertise, and global infrastructure create a moat that justifies its position as the industry's indispensable partner. The bull case — articulated forcefully by management — is that AI makes that moat wider, not narrower, by increasing demand for the data foundations and healthcare-grade AI that only IQVIA can provide. The bear case, which sent the stock from roughly $260 to below $160 between late 2025 and early 2026 before a partial recovery to $187, is that general-purpose AI models trained on public biomedical data could commoditize the analytics, consulting, and even clinical trial design services that constitute a material portion of revenue. The answer will emerge over years, not quarters, and it depends on whether IQVIA's data assets are genuinely non-replicable in ways that matter — an empirical question the market is pricing as unresolved.